Silence Therapeutics (SLN) Current Assets (2018 - 2026)

Silence Therapeutics (SLN) has 9 years of Current Assets data on file, last reported at $102.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 39.42% year-over-year to $102.9 million; the trailing twelve-month figure through Mar 2026 stood at $102.9 million (down 39.42% YoY), and the FY2025 full-year result was $118.7 million, down 36.67% from the prior year.
• Current Assets fell to $102.9 million in Q1 2026, from $118.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $187.4 million in Q4 2024 to a low of $100.6 million in Q4 2023.
• A 5-year average of $134.4 million and a median of $126.1 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets surged 86.32% in 2024 and plunged 39.42% in 2026, its largest moves.
• Tracing SLN's Current Assets over 5 years: stood at $113.4 million in 2022, then slipped by 11.33% to $100.6 million in 2023, then surged by 86.32% to $187.4 million in 2024, then tumbled by 36.67% to $118.7 million in 2025, then retreated by 13.32% to $102.9 million in 2026.
• Business Quant data shows SLN's Current Assets at $102.9 million in Q1 2026, $118.7 million in Q4 2025, and $133.6 million in Q3 2025.